Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary
Young Sup Woo,Won-Myong Bahk,Jung Hyun Jeong,Jung Goo Lee,Won Kim,InKi Sohn,Sung Yong Park,Se Hoon Shim,Jeongseok Seo,Il Han Choo,Chan-Mo Yang,Myung Hun Jung,Duk-In Jon,Moon Doo Kim,Bo-Hyun Yoon +14 more
TL;DR: The recommendations of the KMAP-BP 2022 have changed from the previous version, to reflect the evolution of the social culture and healthcare system in Korea and recent evidence regarding pharmacotherapy of bipolar disorder.
read more
Abstract: Objective We revised the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP), first published in 2002 and revised in 2006, 2010, 2014, and 2018, to reflect recent progress in the treatment of bipolar disorder. Methods The questionnaires consisted of 56 items for adult patients and 7 items for child/adolescent patients, and were used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of bipolar disorder. The review committee included 87 Korean psychiatrists and 40 child and adolescent psychiatry experts. Results For treatment of manic episodes, a combination of a mood stabilizer (MS) and atypical antipsychotics (AAP), or monotherapy with MS or AAP were recommended as first-line treatments. Combinations of MS and AAP, or AAP and lamotrigine (LMT) were recommended as first-line treatments for depressive episodes regardless of the severity. Mono-therapy with MS, AAP, or LMT were also first-line treatments for mild to moderate depressive episodes. For mixed features, a combination of MS and AAP, or monotherapy with AAP or MS were recommended as first-line treatments, and a combination of AAP and LMT, or MS and LMT were the first-line treatments for depressive mixed state. Conclusion The recommendations of the KMAP-BP 2022 have changed from the previous version, to reflect the evolution of the social culture and healthcare system in Korea and recent evidence regarding pharmacotherapy of bipolar disorder. The KMAP-BP 2022 provides clinicians with a wealth of information regarding appropriate strategies to treat patients with bipolar disorder.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines
Jung Hyun Jeong,Won-Myong Bahk,Young Sup Woo,Bo-Hyun Yoon,Jung Goo Lee,Won Kim,InKi Sohn,Sung Yong Park,Se Hoon Shim,Jeongseok Seo,Il Han Choo,Chan-Mo Yang,Myung Hun Jung,Duk-In Jon,Moon Doo Kim +14 more
TL;DR: In this paper , the authors compared the recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) with other recently published guidelines for treating bipolar disorder.
8
Rescue strategies for valproic acid overdose poisoning: Case series and literature review
Renzhu Liu,Lu Xiao,Yixiang Hu,Qingzi Yan,Xiang Liu +4 more
TL;DR: This investigation presents guidance for the treatment and management of acute poisoning with VPA in clinical settings and details the three cases of acute poisoning from VPA.
2
Global perspectives on bipolar disorder treatment: in-depth comparative analysis of international guidelines for medication selection.
Kaveesha Fernando
TL;DR: Various international treatment guidelines for bipolar disorder that have been updated after 2014 are explored, shedding light on the factors that influence therapeutic approaches and thus offering insights that could contribute to the ongoing refinement of evidence-based practices in management.
1
Preventive effect of aripiprazole once-monthly on relapse into mood episodes in bipolar disorder: A multicenter, one-year, retrospective, mirror image study.
Young Sup Woo,Jong-Hyun Jeong,Han-Chul Kang,Kwang-Hun Lee,Se Hoon Shim,Young-Joon Kwon,Sang-Yeol Lee,Seung Ho Jang,Y. Park,Duk-In Jon,Myung Hun Jung,Young-Eun Jung,Moon-Doo Kim,InKi Sohn,Sung Yong Park,Min-Kyu Song,Eunsung Lim,Bo-Hyun Yoon,Won-Myong Bahk +18 more
TL;DR: It is suggested that AOM can reduce mood episode relapse and may be clinically beneficial in the treatment of BD patients, potentially reducing issues associated with polypharmacy in some individuals.
1
The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
Seung Hoon Lee,Kyung Ho Lee,Tae Sun Han,C. Han,Won-Myong Bahk,Soo Jung Lee,Ashwin A. Patkar,Prakash S. Masand,Chi-Un Pae +8 more
TL;DR: This study has shown additional benefit of ARPA treatment for MDDA patients in routine practice, however, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
References
On bipolar disorder
TL;DR: People with bipolar disorder experience both dramatic "highs," called manic episodes, and "lows," called depressive episodes, which can last from hours to weeks, and many people have no symptoms between episodes.
1.7K
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
Lakshmi N. Yatham,Sidney H. Kennedy,Sagar V. Parikh,Ayal Schaffer,David J. Bond,Benicio N. Frey,Verinder Sharma,Benjamin I. Goldstein,Soham Rej,Serge Beaulieu,Martin Alda,Glenda MacQueen,Roumen Milev,Arun V. Ravindran,Claire O'Donovan,Diane McIntosh,Raymond W. Lam,Gustavo Vazquez,Flávio Kapczinski,Roger S. McIntyre,Jan Marie Kozicky,Shigenobu Kanba,Beny Lafer,Trisha Suppes,Joseph R. Calabrese,Eduard Vieta,Gin S Malhi,Robert M. Post,Michael Berk +28 more
TL;DR: These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments.
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Gary S. Sachs,Andrew A. Nierenberg,Joseph R. Calabrese,Lauren B. Marangell,Stephen R. Wisniewski,Laszlo Gyulai,Edward S. Friedman,Charles L. Bowden,Mark D. Fossey,Michael J. Ostacher,Terence A. Ketter,Jayendra K. Patel,Peter Hauser,Daniel Rapport,James M. Martinez,Michael H. Allen,David J. Miklowitz,Michael W. Otto,Ellen B. Dennehy,Michael E. Thase +19 more
TL;DR: The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch.
What Is a “Mood Stabilizer”? An Evidence-Based Response
Mark S. Bauer,Landis Mitchner +1 more
TL;DR: The evidence supported a role for lithium as first-line agent for treatment of bipolar disorder when all four treatment roles are considered and highlights unmet needs and promising agents and provides a yardstick for evaluating new treatment strategies.
The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S Malhi,Gin S Malhi,Erica Bell,Erica Bell,Darryl Bassett,Philip Boyce,Philip Boyce,Richard A. Bryant,Philip Hazell,Malcolm Hopwood,Bill Lyndon,Roger T. Mulder,Richard J Porter,Ajeet B. Singh,Greg Murray +14 more
TL;DR: In this article, the authors provide advice and guidance regarding the management of mood disorders, derived from scientific evidence and supplemented by expert clinical consensus to formulate s that maximise the quality of care.
390